Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Cash from Operations (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Cash from Operations readings, the most recent being 2611000.0 for Q4 2017.

  • On a quarterly basis, Cash from Operations fell 103.67% to 2611000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was 14941000.0, a 203.49% decrease, with the full-year FY2025 number at 62341000.0, down 31.88% from a year prior.
  • Cash from Operations hit 2611000.0 in Q4 2017 for Eledon Pharmaceuticals, up from 3417000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 7578000.0 in Q2 2016 to a low of 11104000.0 in Q1 2015.
  • Median Cash from Operations over the past 5 years was 5421000.0 (2014), compared with a mean of 5237764.71.
  • Biggest five-year swings in Cash from Operations: surged 168.86% in 2016 and later tumbled 205.98% in 2017.
  • Eledon Pharmaceuticals' Cash from Operations stood at 6821000.0 in 2013, then rose by 5.29% to 6460000.0 in 2014, then tumbled by 37.41% to 8877000.0 in 2015, then soared by 85.56% to 1282000.0 in 2016, then crashed by 103.67% to 2611000.0 in 2017.
  • The last three reported values for Cash from Operations were 2611000.0 (Q4 2017), 3417000.0 (Q3 2017), and 8031000.0 (Q2 2017) per Business Quant data.